TSPO-PET

Tiziana Doses First Participants in ALS Foralumab Trial

BOSTON, Mass. — September 28, 2026 Tiziana Life Sciences, Ltd. announced that the first three participants have been dosed...

By cGxPwire Editor
September 29, 2026

.Clinical

Elixiron Reports Positive Phase 2 Enrupatinib Data in Alzheimer’s Disease

CAMBRIDGE, Mass. and TAIPEI, June 10, 2026 Elixiron Immunotherapeutics announced positive interim results from its ongoing Phase 2 proof-of-concept...

By cGxPwire Editor
June 12, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

TSPO-PET

Tiziana Doses First Participants in ALS Foralumab Trial

Elixiron Reports Positive Phase 2 Enrupatinib Data in Alzheimer’s Disease